Company intelligence / Profile preview

Guangzhou Bioseal Biotech

Guangzhou / 廣州, Guangdong Sheng / CN-GD, Chinabioseal.com.cn ↗

Ownership: Private
Development stage: Other

Overview

The company developed and commercialized BIOSEAL™, the first porcine plasma-derived fibrin sealant approved for use in China to control surgical bleeding. Clinical studies have evaluated its safety and efficacy as an adjunct to dura mater repair during elective cranial surgery. The product has been integrated into Johnson & Johnson’s Ethicon biosurgery portfolio following acquisition[1][2].

Therapeutic areas: HematologyNeurology
Modalities: BiologicProteinRecombinant proteinFibrin sealant (porcine plasma-derived)
Industry: Surgical Medical Devices

Partnerships

Integrated with Ethicon’s biosurgery business post-acquisition; no external partnerships disclosed

Beyond the preview

Go deeper on Guangzhou Bioseal Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Bioseal Biotech.

Explore the full profile